1312693-69-8 Usage
Uses
Used in Pharmaceutical Research and Development:
3H-Pyrrolo[3,4-c]pyridin-3-one, 4,6-dichloro-7-fluoro-1,2-dihydrois used as a building block for the synthesis of novel drug candidates due to its unique heterocyclic structure and potential biological activities. Its incorporation into new compounds may lead to the discovery of pharmaceuticals with specific therapeutic effects.
Used in Analytical Chemistry:
In the field of analytical chemistry, 3H-Pyrrolo[3,4-c]pyridin-3-one, 4,6-dichloro-7-fluoro-1,2-dihydrois used as a reference standard. Its defined chemical properties make it suitable for calibration and quality control processes, ensuring the accuracy and reliability of analytical measurements and methods.
Check Digit Verification of cas no
The CAS Registry Mumber 1312693-69-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,2,6,9 and 3 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1312693-69:
(9*1)+(8*3)+(7*1)+(6*2)+(5*6)+(4*9)+(3*3)+(2*6)+(1*9)=148
148 % 10 = 8
So 1312693-69-8 is a valid CAS Registry Number.
1312693-69-8Relevant articles and documents
SOLID STATE FORMS OF FUSED HETEROAROMATIC PYRROLIDINONES
-
Paragraph 0296-0297, (2016/07/05)
Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((lR,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1 -methyl-1H- pyrazol-4-yl)-lH-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
FUSED HETEROAROMATIC PYRROLIDINONES
-
Page/Page column 100, (2011/07/06)
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.